{"id":350361,"date":"2026-11-17T14:40:31","date_gmt":"2026-11-17T09:10:31","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=350361"},"modified":"2026-11-17T14:40:31","modified_gmt":"2026-11-17T09:10:31","slug":"caplin-point-vs-grindwell-norton-vs-fine-organic-vs-dr-lal-pathlabs-vs-kansai-nerolac-low-debt-mid-cap-stocks","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/caplin-point-vs-grindwell-norton-vs-fine-organic-vs-dr-lal-pathlabs-vs-kansai-nerolac-low-debt-mid-cap-stocks\/","title":{"rendered":"Top Low-Debt Mid-Cap Stocks Compared: Caplin Point vs Grindwell Norton vs Fine Organic vs Dr Lal PathLabs vs Kansai Nerolac on Price, Valuation, Q2 FY27 Results and Risks"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Previous close: Caplin Point Rs 2,346.80, Grindwell Norton Rs 1,844.70, Fine Organic Rs 5,277.00, Dr Lal PathLabs Rs 2,000.70, Kansai Nerolac Rs 197.94.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">This low-debt mid-cap stocks compared snapshot checks five names on price, valuation and Q2 FY27 results: Caplin Point, Grindwell Norton, Fine Organic, Dr Lal PathLabs and Kansai Nerolac. Dr Lal PathLabs is the largest by market capitalisation at Rs 33,431 crore. Dr Lal PathLabs reports the highest return on equity at 21.32%. Low-debt mid-cap companies come from different industries, so read each multiple next to margins and returns.<\/p>\n<\/p><\/div>\n<p><strong>Low-debt mid-cap stocks compared<\/strong> here means Caplin Point, Grindwell Norton, Fine Organic, Dr Lal PathLabs and Kansai Nerolac on one page, checked on previous close, market value, valuation and the latest quarterly numbers. The group covers a pharma exporter, an abrasives producer, a specialty additive maker, a diagnostics chain and a paint maker, so each name runs with little debt in a different industry, which is exactly why a side-by-side look helps.<\/p>\n<p>All five companies have filed their September 2026 quarter, so every result below is Q2 FY27. Low-debt mid-cap stocks follow cash generation, margins and sector demand, so a glance at the <a href=\"https:\/\/univest.in\/indices\/nifty-midcap-100\/nifty-midcap-100-share-price-today\">Nifty Midcap 100<\/a> page and the <a href=\"https:\/\/univest.in\/indices\/sensex\/sensex-share-price-today\">Sensex<\/a> page before you read the tables gives useful backdrop.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=low-debt-mid-cap-stocks-compared\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/caplin-point-vs-grindwell-norton-vs-fine-organic-vs-dr-lal-pathlabs-vs-kansai-nerolac-low-debt-mid-cap-stocks\/#Low-Debt_Mid-Cap_Stocks_Compared_Five_Names_on_the_List\" title=\"Low-Debt Mid-Cap Stocks Compared: Five Names on the List\">Low-Debt Mid-Cap Stocks Compared: Five Names on the List<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/caplin-point-vs-grindwell-norton-vs-fine-organic-vs-dr-lal-pathlabs-vs-kansai-nerolac-low-debt-mid-cap-stocks\/#Low-Debt_Mid-Cap_Stocks_Valuation_Multiples_Returns_and_Payouts\" title=\"Low-Debt Mid-Cap Stocks Valuation: Multiples, Returns and Payouts\">Low-Debt Mid-Cap Stocks Valuation: Multiples, Returns and Payouts<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/caplin-point-vs-grindwell-norton-vs-fine-organic-vs-dr-lal-pathlabs-vs-kansai-nerolac-low-debt-mid-cap-stocks\/#Low-Debt_Mid-Cap_Stocks_Q2_FY27_Results_Revenue_and_Profit_Check\" title=\"Low-Debt Mid-Cap Stocks Q2 FY27 Results: Revenue and Profit Check\">Low-Debt Mid-Cap Stocks Q2 FY27 Results: Revenue and Profit Check<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/caplin-point-vs-grindwell-norton-vs-fine-organic-vs-dr-lal-pathlabs-vs-kansai-nerolac-low-debt-mid-cap-stocks\/#Caplin_Point_Results_Snapshot\" title=\"Caplin Point Results Snapshot\">Caplin Point Results Snapshot<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/caplin-point-vs-grindwell-norton-vs-fine-organic-vs-dr-lal-pathlabs-vs-kansai-nerolac-low-debt-mid-cap-stocks\/#Grindwell_Norton_Results_Snapshot\" title=\"Grindwell Norton Results Snapshot\">Grindwell Norton Results Snapshot<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/caplin-point-vs-grindwell-norton-vs-fine-organic-vs-dr-lal-pathlabs-vs-kansai-nerolac-low-debt-mid-cap-stocks\/#Fine_Organic_Results_Snapshot\" title=\"Fine Organic Results Snapshot\">Fine Organic Results Snapshot<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/caplin-point-vs-grindwell-norton-vs-fine-organic-vs-dr-lal-pathlabs-vs-kansai-nerolac-low-debt-mid-cap-stocks\/#Dr_Lal_PathLabs_Results_Snapshot\" title=\"Dr Lal PathLabs Results Snapshot\">Dr Lal PathLabs Results Snapshot<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/caplin-point-vs-grindwell-norton-vs-fine-organic-vs-dr-lal-pathlabs-vs-kansai-nerolac-low-debt-mid-cap-stocks\/#Kansai_Nerolac_Results_Snapshot\" title=\"Kansai Nerolac Results Snapshot\">Kansai Nerolac Results Snapshot<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/caplin-point-vs-grindwell-norton-vs-fine-organic-vs-dr-lal-pathlabs-vs-kansai-nerolac-low-debt-mid-cap-stocks\/#Low-Debt_Mid-Cap_Stocks_Compared_Two_at_a_Time_Three_Pairings\" title=\"Low-Debt Mid-Cap Stocks Compared Two at a Time: Three Pairings\">Low-Debt Mid-Cap Stocks Compared Two at a Time: Three Pairings<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/caplin-point-vs-grindwell-norton-vs-fine-organic-vs-dr-lal-pathlabs-vs-kansai-nerolac-low-debt-mid-cap-stocks\/#Caplin_Point_vs_Fine_Organic\" title=\"Caplin Point vs Fine Organic\">Caplin Point vs Fine Organic<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/caplin-point-vs-grindwell-norton-vs-fine-organic-vs-dr-lal-pathlabs-vs-kansai-nerolac-low-debt-mid-cap-stocks\/#Grindwell_Norton_vs_Kansai_Nerolac\" title=\"Grindwell Norton vs Kansai Nerolac\">Grindwell Norton vs Kansai Nerolac<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/caplin-point-vs-grindwell-norton-vs-fine-organic-vs-dr-lal-pathlabs-vs-kansai-nerolac-low-debt-mid-cap-stocks\/#Dr_Lal_PathLabs_vs_Caplin_Point\" title=\"Dr Lal PathLabs vs Caplin Point\">Dr Lal PathLabs vs Caplin Point<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/caplin-point-vs-grindwell-norton-vs-fine-organic-vs-dr-lal-pathlabs-vs-kansai-nerolac-low-debt-mid-cap-stocks\/#Best_Low-Debt_Mid-Cap_Stocks_for_Each_Type_of_Investor\" title=\"Best Low-Debt Mid-Cap Stocks for Each Type of Investor\">Best Low-Debt Mid-Cap Stocks for Each Type of Investor<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/caplin-point-vs-grindwell-norton-vs-fine-organic-vs-dr-lal-pathlabs-vs-kansai-nerolac-low-debt-mid-cap-stocks\/#What_Is_Driving_Low-Debt_Mid-Cap_Stocks_Right_Now\" title=\"What Is Driving Low-Debt Mid-Cap Stocks Right Now?\">What Is Driving Low-Debt Mid-Cap Stocks Right Now?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/caplin-point-vs-grindwell-norton-vs-fine-organic-vs-dr-lal-pathlabs-vs-kansai-nerolac-low-debt-mid-cap-stocks\/#Risks_to_Weigh_When_You_Compare_Low-Debt_Mid-Cap_Stocks\" title=\"Risks to Weigh When You Compare Low-Debt Mid-Cap Stocks\">Risks to Weigh When You Compare Low-Debt Mid-Cap Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/caplin-point-vs-grindwell-norton-vs-fine-organic-vs-dr-lal-pathlabs-vs-kansai-nerolac-low-debt-mid-cap-stocks\/#How_to_Compare_Low-Debt_Mid-Cap_Stocks_and_Build_a_Shortlist\" title=\"How to Compare Low-Debt Mid-Cap Stocks and Build a Shortlist\">How to Compare Low-Debt Mid-Cap Stocks and Build a Shortlist<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/caplin-point-vs-grindwell-norton-vs-fine-organic-vs-dr-lal-pathlabs-vs-kansai-nerolac-low-debt-mid-cap-stocks\/#Conclusion_Low-Debt_Mid-Cap_Stocks_Compared_at_a_Glance\" title=\"Conclusion: Low-Debt Mid-Cap Stocks Compared at a Glance\">Conclusion: Low-Debt Mid-Cap Stocks Compared at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/caplin-point-vs-grindwell-norton-vs-fine-organic-vs-dr-lal-pathlabs-vs-kansai-nerolac-low-debt-mid-cap-stocks\/#Frequently_Asked_Questions_on_Low-Debt_Mid-Cap_Stocks_Compared\" title=\"Frequently Asked Questions on Low-Debt Mid-Cap Stocks Compared\">Frequently Asked Questions on Low-Debt Mid-Cap Stocks Compared<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/caplin-point-vs-grindwell-norton-vs-fine-organic-vs-dr-lal-pathlabs-vs-kansai-nerolac-low-debt-mid-cap-stocks\/#Which_are_the_top_low-debt_mid-cap_stocks_compared_in_this_article\" title=\"Which are the top low-debt mid-cap stocks compared in this article?\">Which are the top low-debt mid-cap stocks compared in this article?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/caplin-point-vs-grindwell-norton-vs-fine-organic-vs-dr-lal-pathlabs-vs-kansai-nerolac-low-debt-mid-cap-stocks\/#Which_low-debt_mid-cap_stock_has_the_highest_market_capitalisation\" title=\"Which low-debt mid-cap stock has the highest market capitalisation?\">Which low-debt mid-cap stock has the highest market capitalisation?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/caplin-point-vs-grindwell-norton-vs-fine-organic-vs-dr-lal-pathlabs-vs-kansai-nerolac-low-debt-mid-cap-stocks\/#Which_of_these_low-debt_mid-cap_stocks_has_the_lowest_price_to_earnings_ratio\" title=\"Which of these low-debt mid-cap stocks has the lowest price to earnings ratio?\">Which of these low-debt mid-cap stocks has the lowest price to earnings ratio?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/caplin-point-vs-grindwell-norton-vs-fine-organic-vs-dr-lal-pathlabs-vs-kansai-nerolac-low-debt-mid-cap-stocks\/#Which_low-debt_mid-cap_stock_has_the_highest_return_on_equity\" title=\"Which low-debt mid-cap stock has the highest return on equity?\">Which low-debt mid-cap stock has the highest return on equity?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/caplin-point-vs-grindwell-norton-vs-fine-organic-vs-dr-lal-pathlabs-vs-kansai-nerolac-low-debt-mid-cap-stocks\/#How_did_low-debt_mid-cap_stocks_perform_in_Q2_FY27_results\" title=\"How did low-debt mid-cap stocks perform in Q2 FY27 results?\">How did low-debt mid-cap stocks perform in Q2 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/caplin-point-vs-grindwell-norton-vs-fine-organic-vs-dr-lal-pathlabs-vs-kansai-nerolac-low-debt-mid-cap-stocks\/#What_are_the_main_risks_when_you_compare_low-debt_mid-cap_stocks\" title=\"What are the main risks when you compare low-debt mid-cap stocks?\">What are the main risks when you compare low-debt mid-cap stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/caplin-point-vs-grindwell-norton-vs-fine-organic-vs-dr-lal-pathlabs-vs-kansai-nerolac-low-debt-mid-cap-stocks\/#Which_metrics_matter_most_when_you_compare_Low-Debt_Mid-Cap_stocks\" title=\"Which metrics matter most when you compare Low-Debt Mid-Cap stocks?\">Which metrics matter most when you compare Low-Debt Mid-Cap stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/caplin-point-vs-grindwell-norton-vs-fine-organic-vs-dr-lal-pathlabs-vs-kansai-nerolac-low-debt-mid-cap-stocks\/#Which_is_the_best_low-debt_mid-cap_stock_to_buy_among_these_five\" title=\"Which is the best low-debt mid-cap stock to buy among these five?\">Which is the best low-debt mid-cap stock to buy among these five?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Low-Debt_Mid-Cap_Stocks_Compared_Five_Names_on_the_List\"><\/span><strong>Low-Debt Mid-Cap Stocks Compared: Five Names on the List<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The low-debt mid-cap stocks compared here are Caplin Point, Grindwell Norton, Fine Organic, Dr Lal PathLabs and Kansai Nerolac. Dr Lal PathLabs is the largest by <strong>market capitalisation<\/strong> at Rs 33,431 crore. Previous closes run from Rs 197.94 for Kansai Nerolac to Rs 5,277.00 for Fine Organic, which is why a side-by-side look at value rather than price is more useful. This <strong>low-debt mid-cap stocks compared<\/strong> list is the base for every table that follows.<\/p>\n<table>\n<thead>\n<tr>\n<th>Stock<\/th>\n<th>Previous close (Rs)<\/th>\n<th>Market cap (Rs crore)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><a href=\"https:\/\/univest.in\/stocks\/caplipoint\/caplin-point-laboratories-ltd-share-price-today\">Caplin Point<\/a><\/td>\n<td>2,346.80<\/td>\n<td>18,155<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/univest.in\/stocks\/grindwell\/grindwell-norton-ltd-share-price-today\">Grindwell Norton<\/a><\/td>\n<td>1,844.70<\/td>\n<td>21,680<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/univest.in\/stocks\/fineorg\/fine-organic-industries-ltd-share-price-today\">Fine Organic<\/a><\/td>\n<td>5,277.00<\/td>\n<td>16,299<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/univest.in\/stocks\/lalpathlab\/dr-lal-pathlabs-ltd-share-price-today\">Dr Lal PathLabs<\/a><\/td>\n<td>2,000.70<\/td>\n<td>33,431<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/univest.in\/stocks\/kansainer\/kansai-nerolac-paints-ltd-share-price-today\">Kansai Nerolac<\/a><\/td>\n<td>197.94<\/td>\n<td>16,258<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>A quick look at the business behind each ticker puts the numbers in context. Caplin Point makes and sells pharma products in Latin America and Africa, while Grindwell Norton makes abrasives and ceramics. Fine Organic makes oleochemical additives for food and plastics, and Dr Lal PathLabs runs diagnostic labs and collection centres. To compare low-debt mid-cap stocks properly, line up <strong>price to earnings<\/strong>, <strong>return on equity<\/strong> and debt to equity before forming a view.<\/p>\n<p>Rounding out the group, Kansai Nerolac makes decorative and industrial paints. A fair low-debt mid-cap stock comparison looks at what each company actually earns from, not only at the share price. <strong>A services chain and a manufacturer belong in separate mental boxes whenever you compare low-debt mid-cap stocks fairly.<\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Low-Debt_Mid-Cap_Stocks_Valuation_Multiples_Returns_and_Payouts\"><\/span><strong>Low-Debt Mid-Cap Stocks Valuation: Multiples, Returns and Payouts<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Caplin Point trades at the lowest <strong>price to earnings<\/strong> ratio in this group at 25.93. Dr Lal PathLabs reports the highest <strong>return on equity<\/strong> at 21.32%. Kansai Nerolac has the lowest <strong>price to book<\/strong> value at 2.36. These <strong>low-debt mid-cap stocks valuation<\/strong> readings come from the previous close and the latest reported financials. That is the idea behind this <strong>low-debt mid-cap stocks compared<\/strong> table: <strong>price to earnings<\/strong> and <strong>return on equity<\/strong> sit side by side so a high or low reading stands out at once.<\/p>\n<table>\n<thead>\n<tr>\n<th>Stock<\/th>\n<th>Price to earnings<\/th>\n<th>Price to book<\/th>\n<th>ROE (%)<\/th>\n<th>Dividend yield (%)<\/th>\n<th>Debt to equity<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Caplin Point<\/td>\n<td>25.93<\/td>\n<td>4.65<\/td>\n<td>17.88<\/td>\n<td>0.33<\/td>\n<td>0.00<\/td>\n<\/tr>\n<tr>\n<td>Grindwell Norton<\/td>\n<td>46.79<\/td>\n<td>8.34<\/td>\n<td>17.76<\/td>\n<td>0.97<\/td>\n<td>0.02<\/td>\n<\/tr>\n<tr>\n<td>Fine Organic<\/td>\n<td>33.84<\/td>\n<td>5.56<\/td>\n<td>16.44<\/td>\n<td>0.21<\/td>\n<td>0.06<\/td>\n<\/tr>\n<tr>\n<td>Dr Lal PathLabs<\/td>\n<td>56.86<\/td>\n<td>12.18<\/td>\n<td>21.32<\/td>\n<td>1.03<\/td>\n<td>0.09<\/td>\n<\/tr>\n<tr>\n<td>Kansai Nerolac<\/td>\n<td>27.13<\/td>\n<td>2.36<\/td>\n<td>8.88<\/td>\n<td>1.87<\/td>\n<td>0.04<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Price to earnings, return on equity, debt to equity and <strong>dividend yield<\/strong> give the clearest picture of valuation, returns and balance sheet room across the five names. <strong>Earnings per share<\/strong> and <strong>book value<\/strong> per share are the building blocks behind price to earnings and <strong>price to book<\/strong>, so a glance at both in each filing is time well spent. A simple low-debt mid-cap stock comparison like this one is only as useful as the context behind it, which is why debt to equity is worth checking as well.<\/p>\n<p>In this group, price to earnings runs from 25.93 for Caplin Point to 56.86 for Dr Lal PathLabs. Kansai Nerolac offers the highest <strong>dividend yield<\/strong> at 1.87%. Industry price to earnings readings differ by sub-sector: Caplin Point at 40.55; Grindwell Norton at 42.97; Fine Organic at 33.54; Dr Lal PathLabs at 62.49; Kansai Nerolac at 45.18. The industry price to earnings is a handy anchor: a stock above it is priced for faster growth, and one below it is priced for steadier earnings. <strong>A well-built low-debt mid-cap stock comparison also notes that low debt does not replace a look at valuation.<\/strong> Run the same low-debt mid-cap stock comparison on your own watchlist and the pattern in these numbers will be easier to spot.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Low-Debt_Mid-Cap_Stocks_Q2_FY27_Results_Revenue_and_Profit_Check\"><\/span><strong>Low-Debt Mid-Cap Stocks Q2 FY27 Results: Revenue and Profit Check<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>All of the five low-debt mid-cap stocks compared have filed Q2 FY27 numbers. Fine Organic posted the fastest revenue growth at 22.9% year on year. Fine Organic showed the sharpest rise in net profit at 40.1%. Read revenue first and <strong>quarterly profit<\/strong> second, since the two together show how much of the growth reaches shareholders. Treat the Q2 FY27 numbers in this <strong>low-debt mid-cap stocks compared<\/strong> review as a snapshot of one quarter, not a verdict on any mid-cap company.<\/p>\n<table>\n<thead>\n<tr>\n<th>Stock<\/th>\n<th>Q2 FY27 revenue (Rs crore)<\/th>\n<th>Q2 FY26 revenue (Rs crore)<\/th>\n<th>Q2 FY27 net profit (Rs crore)<\/th>\n<th>Q2 FY26 net profit (Rs crore)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Caplin Point<\/td>\n<td>663.1<\/td>\n<td>564.4<\/td>\n<td>182.3<\/td>\n<td>160.2<\/td>\n<\/tr>\n<tr>\n<td>Grindwell Norton<\/td>\n<td>923.1<\/td>\n<td>805.7<\/td>\n<td>133.2<\/td>\n<td>107.4<\/td>\n<\/tr>\n<tr>\n<td>Fine Organic<\/td>\n<td>760.0<\/td>\n<td>618.4<\/td>\n<td>152.1<\/td>\n<td>108.5<\/td>\n<\/tr>\n<tr>\n<td>Dr Lal PathLabs<\/td>\n<td>908.2<\/td>\n<td>755.4<\/td>\n<td>193.9<\/td>\n<td>152.2<\/td>\n<\/tr>\n<tr>\n<td>Kansai Nerolac<\/td>\n<td>2,352<\/td>\n<td>1,983<\/td>\n<td>144.0<\/td>\n<td>133.3<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"Caplin_Point_Results_Snapshot\"><\/span><strong>Caplin Point Results Snapshot<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Caplin Point reported Q2 FY27 revenue of <strong>Rs 663.1 crore<\/strong>, compared with <strong>Rs 564.4 crore<\/strong> a year earlier, a rise of <strong>17.5%<\/strong>. Net profit rose 13.8% to Rs 182.3 crore from Rs 160.2 crore. <strong>Earnings per share<\/strong> for the quarter rose to Rs 23.37 from Rs 20.25.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Grindwell_Norton_Results_Snapshot\"><\/span><strong>Grindwell Norton Results Snapshot<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>In the September 2026 quarter, Grindwell Norton booked revenue of <strong>Rs 923.1 crore<\/strong> against <strong>Rs 805.7 crore<\/strong> in the same quarter last year, a rise of <strong>14.6%<\/strong>. Net profit rose 24.0% to Rs 133.2 crore from Rs 107.4 crore. Operating margin expanded to 23.4% from 22.2% a year ago. <strong>Earnings per share<\/strong> for the quarter rose to Rs 11.99 from Rs 9.65.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Fine_Organic_Results_Snapshot\"><\/span><strong>Fine Organic Results Snapshot<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Fine Organic&#8217;s Q2 FY27 top line stood at <strong>Rs 760.0 crore<\/strong>, versus <strong>Rs 618.4 crore<\/strong> in Q2 FY26, a rise of <strong>22.9%<\/strong>. Net profit rose 40.1% to Rs 152.1 crore from Rs 108.5 crore. Operating margin expanded to 29.2% from 26.0% a year ago. Earnings per share for the quarter rose to Rs 49.62 from Rs 35.40.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Dr_Lal_PathLabs_Results_Snapshot\"><\/span><strong>Dr Lal PathLabs Results Snapshot<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Dr Lal PathLabs reported Q2 FY27 revenue of <strong>Rs 908.2 crore<\/strong>, compared with <strong>Rs 755.4 crore<\/strong> a year earlier, a rise of <strong>20.2%<\/strong>. Net profit rose 27.4% to Rs 193.9 crore from Rs 152.2 crore. Operating margin expanded to 36.0% from 34.1% a year ago.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Kansai_Nerolac_Results_Snapshot\"><\/span><strong>Kansai Nerolac Results Snapshot<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>In the September 2026 quarter, Kansai Nerolac booked revenue of <strong>Rs 2,352 crore<\/strong> against <strong>Rs 1,983 crore<\/strong> in the same quarter last year, a rise of <strong>18.7%<\/strong>. Net profit rose 8.0% to Rs 144.0 crore from Rs 133.3 crore. Earnings per share for the quarter rose to Rs 1.81 from Rs 1.67.<\/p>\n<p>Cash generation, margins and sector demand shape these stocks, and a light balance sheet adds room to grow, so profit can look different from revenue in a single quarter. That is why a low-debt mid-cap stock comparison works best when revenue and profit are read together across two or three quarters. Used this way, a <strong>low-debt mid-cap stocks compared<\/strong> review becomes a map of the sector rather than a price list. When you compare low-debt mid-cap stocks after each result season, track how debt to equity changes from one quarter to the next.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Low-Debt_Mid-Cap_Stocks_Compared_Two_at_a_Time_Three_Pairings\"><\/span><strong>Low-Debt Mid-Cap Stocks Compared Two at a Time: Three Pairings<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Readers rarely want a five-way table and nothing else, so here are three head-to-head reads drawn from the same data. Use them as a quick way to compare low-debt mid-cap stocks two at a time.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Caplin_Point_vs_Fine_Organic\"><\/span><strong>Caplin Point vs Fine Organic<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Caplin Point and Fine Organic both run lean balance sheets with high margins. The two are close in size, with <strong>market capitalisation<\/strong>s of Rs 18,155 crore for Caplin Point and Rs 16,299 crore for Fine Organic. On price to earnings, Caplin Point carries the lower multiple at 25.93 against 33.84 for Fine Organic. Caplin Point reports the higher return on equity, at 17.88% against 16.44% for Fine Organic. Two niche leaders, so read margins next to valuation.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Grindwell_Norton_vs_Kansai_Nerolac\"><\/span><strong>Grindwell Norton vs Kansai Nerolac<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Grindwell makes industrial abrasives, while Kansai Nerolac makes paints. On price to earnings, Kansai Nerolac carries the lower multiple at 27.13 against 46.79 for Grindwell Norton. Grindwell Norton reports the higher return on equity, at 17.76% against 8.88% for Kansai Nerolac. For dividend income, Kansai Nerolac offers 1.87% against 0.97% at Grindwell Norton. Two industrial suppliers with different customers, so compare returns first.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Dr_Lal_PathLabs_vs_Caplin_Point\"><\/span><strong>Dr Lal PathLabs vs Caplin Point<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Dr Lal PathLabs runs diagnostic centres, while Caplin Point sells pharma products. Dr Lal PathLabs reports the higher return on equity, at 21.32% against 17.88% for Caplin Point. For dividend income, Dr Lal PathLabs offers 1.03% against 0.33% at Caplin Point. In Q2 FY27, Dr Lal PathLabs grew revenue faster, at 20.2% year on year against 17.5% for Caplin Point. A services chain and a product exporter follow different drivers.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Best_Low-Debt_Mid-Cap_Stocks_for_Each_Type_of_Investor\"><\/span><strong>Best Low-Debt Mid-Cap Stocks for Each Type of Investor<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Which of the <strong>best low-debt mid-cap stocks<\/strong> is right for you depends on your priorities, so the table below lists the leader on each measure instead of crowning one name. Any <strong>low-debt mid-cap stocks compared<\/strong> table can mislead if you stop at one row, because each mid-cap company leads on a different measure.<\/p>\n<table>\n<thead>\n<tr>\n<th>If you care most about<\/th>\n<th>Start your research with<\/th>\n<th>The number<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Lowest price to earnings<\/td>\n<td>Caplin Point<\/td>\n<td>25.93<\/td>\n<\/tr>\n<tr>\n<td>Highest return on equity<\/td>\n<td>Dr Lal PathLabs<\/td>\n<td>21.32%<\/td>\n<\/tr>\n<tr>\n<td>Highest dividend yield<\/td>\n<td>Kansai Nerolac<\/td>\n<td>1.87%<\/td>\n<\/tr>\n<tr>\n<td>Lowest price to book value<\/td>\n<td>Kansai Nerolac<\/td>\n<td>2.36<\/td>\n<\/tr>\n<tr>\n<td>Largest by market capitalisation<\/td>\n<td>Dr Lal PathLabs<\/td>\n<td>Rs 33,431 crore<\/td>\n<\/tr>\n<tr>\n<td>Fastest Q2 FY27 revenue growth<\/td>\n<td>Fine Organic<\/td>\n<td>22.9%<\/td>\n<\/tr>\n<tr>\n<td>Sharpest Q2 FY27 net profit rise<\/td>\n<td>Fine Organic<\/td>\n<td>40.1%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>No single name tops every row, which is exactly why a low-debt mid-cap stock comparison helps. Balance sheets, margins and valuation point to different companies, so decide what matters most to you before you rank the numbers.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Is_Driving_Low-Debt_Mid-Cap_Stocks_Right_Now\"><\/span><strong>What Is Driving Low-Debt Mid-Cap Stocks Right Now?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Mid-sized companies with very little debt can fund growth from their own cash and keep interest costs low. Knowing what moves sector demand and cash generation helps you compare low-debt mid-cap stocks with the right questions in mind.<\/p>\n<p>A strong balance sheet helps in slow phases, though valuation and growth still decide the outcome. A good <strong>low-debt mid-cap stocks compared<\/strong> routine therefore tracks cash generation, margins and capacity plans.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Risks_to_Weigh_When_You_Compare_Low-Debt_Mid-Cap_Stocks\"><\/span><strong>Risks to Weigh When You Compare Low-Debt Mid-Cap Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Low-Debt Mid-Cap stocks depend on demand, input costs, policy and the wider market mood. Valuations differ by company, so read each filing for order, volume and margin commentary before you compare them. Every low-debt mid-cap stock comparison has blind spots, and for this group the biggest is sector demand and cash generation.<\/p>\n<p>Because cash generation, margins and capacity plans drive these businesses, the most useful habit is to read the management commentary that comes with every result and note what is expected for the next quarter. Read together, the risk notes and the tables make this <strong>low-debt mid-cap stocks compared<\/strong> guide a balanced starting point.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Compare_Low-Debt_Mid-Cap_Stocks_and_Build_a_Shortlist\"><\/span><strong>How to Compare Low-Debt Mid-Cap Stocks and Build a Shortlist<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Start by deciding which low debt business suits your view, because each reads the market differently. Readers who follow cash generation, margins and capacity plans find the group easier to track. Done step by step, this <strong>low-debt mid-cap stocks compared<\/strong> routine becomes repeatable rather than a one-off exercise.<\/p>\n<p>Then check valuation and returns, because the five names rarely trade on the same multiple. A diagnostics chain next to an additive maker shows how the business behind each price changes the numbers. Keep the shortlist of <strong>best low-debt mid-cap stocks<\/strong> short enough that you can actually follow each company&#8217;s quarterly results. When you compare low-debt mid-cap stocks again after new results, update only the rows that changed instead of starting over.<\/p>\n<p>The Univest stock screener lets you filter low-debt mid-cap stocks by <strong>market capitalisation<\/strong>, return on equity and price to earnings, and the app keeps live prices a tap away through the trading day. Come back to this <strong>low-debt mid-cap stocks compared<\/strong> page after the next set of results to see which numbers have moved.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for live low-debt mid-cap stock data<\/strong><\/a><\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track these low-debt mid-cap stocks live.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion_Low-Debt_Mid-Cap_Stocks_Compared_at_a_Glance\"><\/span><strong>Conclusion: Low-Debt Mid-Cap Stocks Compared at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>This low-debt mid-cap stocks compared review on price, valuation and Q2 FY27 results shows that no single name wins every measure. Dr Lal PathLabs leads on both size and return on equity, though the others bring strengths of their own. Treat the <strong>low-debt mid-cap stocks Q2 FY27 results<\/strong> and <strong>low-debt mid-cap stocks valuation<\/strong> tables as a research starting point, then check the filings and speak to a SEBI-registered advisor before you invest. If you plan to compare low-debt mid-cap stocks again next quarter, the same checklist of price to earnings, return on equity and debt to equity will work.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Low-Debt_Mid-Cap_Stocks_Compared\"><\/span><strong>Frequently Asked Questions on Low-Debt Mid-Cap Stocks Compared<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Which_are_the_top_low-debt_mid-cap_stocks_compared_in_this_article\"><\/span><strong>Which are the top low-debt mid-cap stocks compared in this article?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The low-debt mid-cap stocks compared in this article are Caplin Point, Grindwell Norton, Fine Organic, Dr Lal PathLabs and Kansai Nerolac. They are checked on previous close, market capitalisation, price to earnings, price to book, return on equity and the latest quarterly results, so the group can be read in one sitting before you go deeper into any single company.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_low-debt_mid-cap_stock_has_the_highest_market_capitalisation\"><\/span><strong>Which low-debt mid-cap stock has the highest market capitalisation?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Among the five names, Dr Lal PathLabs has the highest market capitalisation at Rs 33,431 crore. Grindwell Norton follows at Rs 21,680 crore. Market value changes with every price move, which means the ranking can shuffle, so look at the latest figure on the exchange.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_of_these_low-debt_mid-cap_stocks_has_the_lowest_price_to_earnings_ratio\"><\/span><strong>Which of these low-debt mid-cap stocks has the lowest price to earnings ratio?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> On low-debt mid-cap stocks valuation, Caplin Point has the lowest price to earnings ratio among these low-debt mid-cap stocks at 25.93, based on the latest reported earnings. Dr Lal PathLabs sits at the other end at 56.86. Treat the lowest multiple as a place to start asking questions, because growth and business quality explain why investors pay more or less.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_low-debt_mid-cap_stock_has_the_highest_return_on_equity\"><\/span><strong>Which low-debt mid-cap stock has the highest return on equity?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dr Lal PathLabs reports the highest return on equity in this group at 21.32%. In plain terms, return on equity tells you how hard shareholder funds are working. Read it across a few years and alongside debt, since a high ratio built on borrowing carries more risk.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_did_low-debt_mid-cap_stocks_perform_in_Q2_FY27_results\"><\/span><strong>How did low-debt mid-cap stocks perform in Q2 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> All of the five names have filed Q2 FY27 numbers in our data. Fine Organic recorded the fastest revenue growth at 22.9% year on year. Fine Organic showed the sharpest net profit rise at 40.1%. For low-debt mid-cap stocks Q2 FY27 results, each filing on the exchange website carries the full detail behind these figures.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_risks_when_you_compare_low-debt_mid-cap_stocks\"><\/span><strong>What are the main risks when you compare low-debt mid-cap stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Low-Debt Mid-Cap stocks depend on demand, input costs, policy and the wider market mood. Valuations differ by company, so read each filing for order, volume and margin commentary before you compare them. Keep an eye on cash generation, margins and capacity plans.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_metrics_matter_most_when_you_compare_Low-Debt_Mid-Cap_stocks\"><\/span><strong>Which metrics matter most when you compare Low-Debt Mid-Cap stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Debt to equity, return on equity, operating margin and price to earnings matter most here. A light balance sheet is one factor, so read it next to growth and valuation. Read each filing for margin commentary.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_is_the_best_low-debt_mid-cap_stock_to_buy_among_these_five\"><\/span><strong>Which is the best low-debt mid-cap stock to buy among these five?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The best Low-Debt Mid-Cap stock depends on which low debt business suits your view, because the five names differ on all of these. On the numbers in this article, Dr Lal PathLabs has the largest market capitalisation as well as the highest return on equity; Caplin Point has the lowest price to earnings; Kansai Nerolac has the highest dividend yield. There is no clear winner across every measure, and nothing here is a recommendation. Let the tables narrow your list, confirm the numbers in the filings, and take advice from a SEBI-registered advisor before acting.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Which are the top low-debt mid-cap stocks compared in this article?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The low-debt mid-cap stocks compared in this article are Caplin Point, Grindwell Norton, Fine Organic, Dr Lal PathLabs and Kansai Nerolac. They are checked on previous close, market capitalisation, price to earnings, price to book, return on equity and the latest quarterly results, so the group can be read in one sitting before you go deeper into any single company.\"}},{\"@type\":\"Question\",\"name\":\"Which low-debt mid-cap stock has the highest market capitalisation?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Among the five names, Dr Lal PathLabs has the highest market capitalisation at Rs 33,431 crore. Grindwell Norton follows at Rs 21,680 crore. Market value changes with every price move, which means the ranking can shuffle, so look at the latest figure on the exchange.\"}},{\"@type\":\"Question\",\"name\":\"Which of these low-debt mid-cap stocks has the lowest price to earnings ratio?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"On low-debt mid-cap stocks valuation, Caplin Point has the lowest price to earnings ratio among these low-debt mid-cap stocks at 25.93, based on the latest reported earnings. Dr Lal PathLabs sits at the other end at 56.86. Treat the lowest multiple as a place to start asking questions, because growth and business quality explain why investors pay more or less.\"}},{\"@type\":\"Question\",\"name\":\"Which low-debt mid-cap stock has the highest return on equity?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Dr Lal PathLabs reports the highest return on equity in this group at 21.32%. In plain terms, return on equity tells you how hard shareholder funds are working. Read it across a few years and alongside debt, since a high ratio built on borrowing carries more risk.\"}},{\"@type\":\"Question\",\"name\":\"How did low-debt mid-cap stocks perform in Q2 FY27 results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"All of the five names have filed Q2 FY27 numbers in our data. Fine Organic recorded the fastest revenue growth at 22.9% year on year. Fine Organic showed the sharpest net profit rise at 40.1%. For low-debt mid-cap stocks Q2 FY27 results, each filing on the exchange website carries the full detail behind these figures.\"}},{\"@type\":\"Question\",\"name\":\"What are the main risks when you compare low-debt mid-cap stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Low-Debt Mid-Cap stocks depend on demand, input costs, policy and the wider market mood. Valuations differ by company, so read each filing for order, volume and margin commentary before you compare them. Keep an eye on cash generation, margins and capacity plans.\"}},{\"@type\":\"Question\",\"name\":\"Which metrics matter most when you compare Low-Debt Mid-Cap stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Debt to equity, return on equity, operating margin and price to earnings matter most here. A light balance sheet is one factor, so read it next to growth and valuation. Read each filing for margin commentary.\"}},{\"@type\":\"Question\",\"name\":\"Which is the best low-debt mid-cap stock to buy among these five?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The best Low-Debt Mid-Cap stock depends on which low debt business suits your view, because the five names differ on all of these. On the numbers in this article, Dr Lal PathLabs has the largest market capitalisation as well as the highest return on equity; Caplin Point has the lowest price to earnings; Kansai Nerolac has the highest dividend yield. There is no clear winner across every measure, and nothing here is a recommendation. Let the tables narrow your list, confirm the numbers in the filings, and take advice from a SEBI-registered advisor before acting.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Compare Caplin Point, Grindwell Norton, Fine Organic, Dr Lal PathLabs and Kansai Nerolac on price, valuation and Q2 FY27 results in one place, with the risks to check before you invest.<\/p>\n","protected":false},"author":34,"featured_media":350360,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[24935,24934,24936,24937],"class_list":["post-350361","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-best-low-debt-mid-cap-stocks","tag-low-debt-mid-cap-stocks-compared","tag-low-debt-mid-cap-stocks-q2-fy27-results","tag-low-debt-mid-cap-stocks-valuation"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["350360"],"rank_math_title":["Low-Debt Mid-Cap Stocks: Caplin vs Grindwell vs Fine Organic"],"rank_math_description":["Low-debt mid-cap stocks compared on price, valuation and Q2 FY27 results: Caplin Point, Grindwell Norton, Fine Organic and more, with risks to check."],"rank_math_focus_keyword":["low-debt mid-cap stocks compared"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/top-low-debt-mid-cap-stocks-compared-caplin-point-vs-grindwell-norton-vs-fine.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/350361","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=350361"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/350361\/revisions"}],"predecessor-version":[{"id":350362,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/350361\/revisions\/350362"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/350360"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=350361"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=350361"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=350361"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}